BofA Downgrades Sarepta, But Hikes Price Target By: Benzinga via Benzinga May 21, 2015 at 11:08 AM EDT In a report published Thursday, BofA Merrill Lynch analysts downgraded the rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) to Neutral, ... Read More >> Related Stocks: Sarepta Therapeutics